Rafael Holdings Mourns the Passing of Lead Independent Director, Stephen Greenberg, and Announces the Appointment of Alan Grayson to its Board of Directors

Core Points - Rafael Holdings, Inc. announced the passing of Lead Independent Director Stephen Greenberg and appointed Alan Grayson to the Board of Directors [1][3] - Markus Sieger, an existing Board member, has been elected as Lead Independent Director and will chair the Audit Committee [1][4] Company Overview - Rafael Holdings, Inc. is a biotechnology company focused on developing pharmaceuticals and holding interests in clinical and early-stage companies [5] - The company's lead candidate, Trappsol® Cyclo™, is currently undergoing a pivotal Phase 3 clinical trial for the treatment of Niemann-Pick Disease Type C1 [5]